JDD Buzz Series | Diversity in Melasma Clinical Trials
melasmaUnderrepresentation of patients with skin of color in clinical trials is an issue in medical research, including in research about dermatological conditions. A study in the January Journal of Drugs in Dermatology looked at the diversity of patients enrolled in melasma clinical trials to determine if there are any disparities in representation. I interviewed author Jared Jagdeo, MD, MS, associat …
melasma
JDD Buzz Series | Metformin’s Potential Chemopreventive Effect
metforminA commonly used diabetes medication may help prevent non-melanoma skin cancer. A study in the December Journal of Drugs in Dermatology analyzed whether metformin exposure is associated with a reduced risk of non-melanoma skin cancer. The study also stratified findings by race/ethnicity, which makes it unique among similar research studies. I interviewed author Tiffany Jow Libby, MD, FAAD, FACMS …
metformin
JDD Buzz Series | AI Chatbots in Dermatology
AI Chatbots in dermatologyAre AI chatbots a wave of the future in dermatology? An article in the November Journal of Drugs in Dermatology assessed dermatologists’ attitudes and beliefs toward artificial intelligence chatbots. Chatbot usage has grown in a variety of areas of society in recent years, and ChatGPT’s popularity shows there’s demand. So to what extent do dermatologists think AI chatbots will play a role in …
AI Chatbots in dermatology
JDD Buzz Series | Algorithmic Beauty
Algorithmic BeautyA study in the September Journal of Drugs in Dermatology addressed the impact of social media algorithms on the perception of beauty. While the golden ratio dates back to ancient Greece – and is an ages-old beauty standard for those of European ancestry – beauty ideals of facial features often change over time and vary by region. Yet access to a curated diet of images through social media may …
Algorithmic Beauty
JDD Buzz Series | The Burden of Melasma
melasmaA study in the August Journal of Drugs in Dermatology addressed the burden of melasma – the populations most prone to melasma and the comorbidities associated with it. According to the study’s authors, a deeper understanding of the associations of race, ethnicity and comorbidities can help dermatologists determine which patients are at risk of developing melasma and as well as potential new pa …
melasma